Wenxin Xu, MD

Wenxin Xu, MD, of Dana-Farber Cancer Institute

Articles by Wenxin Xu, MD

CheckMate 214: Post-Hoc Analysis of KIM-1 as a Prognostic Biomarker in aRCC

Wenxin Xu, MDRenal Cell Carcinoma | February 21, 2025

Drs. Xu and Joyce break down the evaluation of circulating KIM-1 as a prognostic and predictive biomarker in advanced RCC.

Plasma KIM-1 as a Preoperative Biomarker for RCC

Wenxin Xu, MDRenal Cell Carcinoma Diagnostics | May 28, 2024

Drs. Xu and Joyce explain the rationale behind recent research on plasma KIM-1, its significance as a biomarker, and more.